Mikhail Blagosklonny’s Contribution to the World of Medicine

Mikhail Blagosklonny is a prominent professor of oncology at the renowned Roswell Park Cancer Institute in New York. He is a known scientist who studies Aging and Cancers. Mikhail has facilitated the development of anti-cancer methods as well as cancer prevention and therapy methods. Moreover, his captivating interests in research are in cellular and molecular biological as well as medical investigation. They include anti-cancer therapeutic, signal transduction, fresh cancer strategies, mitosis, and apoptosis.

Mikhail Blagosklonny has also formulated a hypothesis about the probable role of TOR signaling in cancer and aging. He recommended the use of rapamycin, a popular medicine that acts as a potential treatment for cancer. Scientists are investigating his claims about the treatment. However, Mikhail remains optimistic about the success of rapamycin. Moreover, he is among the most passionate advocates of the medicine in longevity research. Visit classroomvoices.org to read more about Mikhail.

Academic and Career Profile

Mikhail Blagosklonny studied at the First Pavlov State Medical University in St. Petersburg where he earned his master’s degree in internal medicine. Additionally, Mikhail was awarded a Ph.D. in cardiology and experimental medicine from the institution.

His Career journey started when he became an associate professor at the New York Medical College in 2002. Later, Mikhail Blagosklonny became a top scientist at the renowned Ordway Research Institute in Albany. In 2009, he became a professor of oncology at the Roswell Park Cancer Institute.

Achievements of Mikhail Blagosklonny

Mikhail Blagosklonny is a well-known author of over 260 articles that have been published in peer-reviewed journals. Further, Mikhail is an author of the theory of aging hyperfunction, chemotherapeutic engineering, and cell cyclotherapy. Researchers have cited his articles more than 25,000 times. This has earned Mikhail an h-index of 83.

Currently, he is an associate editor of Cell Death Differentiation and Cancer Biology Therapy. Moreover, Mikhail has served on the editorial panel of Cancer Research, Autophagy, International J Cancer, and PLOS ONE. He is also an editor-in-chief of Cell Cycle, Aging, and Oncotarget.

Conclusively, the unwavering commitment of Mikhail in oncology has made him popular and among the best oncology researchers worldwide. He cites that he is driven by his love for people and the vision of living in a disease-free society. Visit ResearchGate.Net to learn more about Mikhail’s latest work.

Mikhail Blagosklonny: Scientist, Professor, and Editor

Mikhail Blagosklonny is one of the foremost experts in oncology of our time. Blagosklonny has a Master’s in Internal Medicine and a Doctorate in Experimental Medicine. He started his career at the New York Medical College as an associate professor of medicine. Mikhail then became a senior scientist at the Ordway Research Institute. One of the factors that led to Blagosklonny’s appointment on LinkedIn was his unique and novel approach to cancer treatment over the years.

Mikhail Blagosklonny’s research at https://en.wikipedia.org/wiki/Mikhail_Blagosklonny has ranged from the cell cycle and molecular biology to cell cycle and anti-cancer strategies. Blagosklonny has been one of the most vocal backers of rapamycin as an anti-ageing drug. This stemmed from his research on TOR signaling and its role in cancer and aging. Blagosklonny observed that continual cell development causes cancer and aging. This means that anything that stops one from happening will also stop the other. Rapamycin is one such drug. It is used in the prevention of the spread of cancer in the body. Tests have shown that indeed rapamycin increases the life span of the individual that takes it. He stated that the drug is not helpful to people with low immunity and should be taken early enough in one’s life for it to be effective.

Mikhail is one of the founders of Oncotarget on ImpactJournals.com. He is one of the journal’s editors-in-chief. Oncotarget publishes papers on oncology and is released on a weekly basis. The peer-reviewed journal has an impact factor of 5.0.  Oncotarget has been praised for allowing scientific studies to be spread widely and rapidly. It has also facilitated the collaboration between scientists from different fields.

Mikhail is also the co-founder and one of the editors-in-chief of Aging and Oncoscience. Mikhail is the associate editor of Cell Death and Differentiation, Autophagy and Cancer Biology & Therapy. He has also been the associate editor of PLOS One, the American Journal of Pathology, and the International Journal of Cancer.